comprehensive -WSS

comprehensive

author：focus 2025-10-01 04:11:29 - browse：6

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： FDA scientists endorse Pfizer/BioNTech Covid

explore

WSS

It costs an awful lot of money to give away a kidney

2 officers injured in shooting in Orlando, police say

Group behind ProMed defends move to subscription

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Dramatically reducing cancer deaths requires the PASTEUR Act

Group behind ProMed defends move to subscription

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

'Null' research findings aren't empty of meaning. Let's publish them

Walensky prepares to leave CDC — and Congress — behind

Biotech startup Celsius cuts 75% of staff ahead of first trial start

How one medical school became remarkably diverse

My superpower is killing ticks

Drug repurposing or repositioning? The language matters

Dramatically reducing cancer deaths requires the PASTEUR Act

United colonoscopy coverage change 'may cost lives,' doctors say

Personalized medicine goes far beyond genetics

entertainment

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Flint parents haunted by uncertainty, fears of lead poisoning

TytoCare raises $49 million to build out AI

focus

explore

explore

Wikipedia